#1
Moderna
The mRNA pioneer that peaked at $18B revenue, outperforming #2 BioNTech by over 4x in peak sales. Beyond COVID, Moderna's platform is attacking flu, HIV, and cancer with personalized mRNA vaccines. Its 2023 RSV vaccine approval validated mRNA as a universal medicine-making technology, with a pipeline value estimated at $50B.
Photos (1)
Comments on "Moderna"
Create a free account or sign in to join the discussion.
Sign in to join the conversation